NCT06011330View on ClinicalTrials.gov

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer

CompletedOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

June 30, 2022

Study Completion Date

February 10, 2023

Conditions
Colorectal Cancer
Interventions
DRUG

Fruquintinib combined with anti-PD-1 antibodies

Fruquintinib (3-5mg once daily for 21 days on/7 days off) anti-PD-1 antibodies (including sintilimab, toripalimab, pembrolizumab, tislelizumab, and nivolumab).

Trial Locations (1)

Unknown

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Cancer Hospital

OTHER

NCT06011330 - Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter